posted on 2023-08-30, 17:54authored byDong Yeon Jeong, Jinhee Lee, Jong Yeob Kim, Keum Hwa Lee, Han Li, Jun Young Lee, Gwang Hun Jeong, Sojung Yoon, Eun Lyeong Park, Sung Hwi Hong, Joon Won Kang, Tae-Jin Song, Thomas Leyhe, Michael Eisenhut, Andreas Kronbichler, Lee Smith, Marco Solmi, Brendon Stubbs, Ai Koyanagi, Louis Jacob, Andrew Stickley, Trevor Thompson, Elena Dragioti, Hans Oh, Andre R. Brunoni, Andre F. Carvalho, Min Seo Kim, Dong Keon Yon, Seung Won Lee, Jee Myung Yang, Ramy A. Ghayda, Jae Il Shin, Paolo Fusar-Poli
OBJECTIVE: Alzheimer’s disease (AD) is a leading cause of years lived with disability in older age, and several cerebrospinal fluid (CSF) markers have been proposed in individual meta-analyses to be associated with AD but field-wide evaluation and scrutiny of the literature is not available.
MATERIALS AND METHODS: We performed an umbrella review for the reported associations between CSF biomarkers and AD. Data from available meta-analyses were reanalyzed using both random and fixed effects models. We also estimated between-study heterogeneity, small-study effects, excess significance, and prediction interval.
RESULTS: A total of 38 meta-analyses on CSF markers from 11 eligible articles were identified and reanalyzed. In 14 (36%) of the meta-analyses, the summary estimate and the results of the largest study showed non-concordant results in terms of statistical significance. Large heterogeneity (I2≥75%) was observed in 73% and small-study effects under Egger’s test were shown in 28% of CSF biomarkers.
CONCLUSIONS: Our results suggest that there is an excess of statistically significant results and significant biases in the literature of CSF biomarkers for AD. Therefore, the results of CSF biomarkers should be interpreted with caution.
History
Refereed
Yes
Volume
25
Issue number
3
Page range
1536-1547
Publication title
European Review for Medical and Pharmacological Sciences